A number of research firms have changed their ratings and price targets for Foghorn Therapeutics (NASDAQ: FHTX): 9/13/2021 – Foghorn Therapeutics was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Foghorn Therapeutics Inc. engages in the discovery and development of medicines targeting genetically determined dependencies […]
